Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Analysis By Segmentations(Type, Application, Source), Size, Trends, Dynamics & Forecast 2023-2032
Global Chronic Inflammatory Demyelinating
Polyneuropathy Market
The expected
CAGR of global chronic inflammatory demyelinating polyneuropathy (CIDP) market
is tend to be around 7.50% in the mentioned forecast period. The market was
valued at USD 1.51 billion in 2022, and it would grow up to USD 2.69 billion by
2032. In addition
to the market insights such as market value, growth rate, market segments,
geographical coverage, market players, and market scenario, the market report
curated by the Data Bridge Market Research team also includes in-depth expert
analysis, patient epidemiology, pipeline analysis, pricing analysis, and
regulatory framework.
Chronic
inflammatory demyelinating polyneuropathy is a type of neurological disorder
wherein the body immune system attacks myelin which is an important part of the
nervous system. This can cause pain, loss of sensation, chronic fatigue,
impaired ability, and other problems. Several treatments can be used to treat
this disease such as intravenous immunoglobulin, plasmapheresis, physiotherapy
and others. This disease occurrence is rising and important diagnostic
procedures and treatments will boost the growth of the market.
Chronic
Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological
disorder that affects the peripheral nerves and causes progressive weakness and
impaired sensation in the limbs. The CIDP treatment market refers to the market
for drugs and therapies used in the treatment of CIDP.
The market is expected to grow significantly in
the coming years, driven by factors such as increasing prevalence of CIDP,
rising awareness about the disorder, and the development of novel.
Get a Free Sample Copy of a
Research Report: https://analyticsmarketresearch.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-(cidp)-treatment-market/76811/
COVID-19 Impact on Global Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP) Market
With respect to the pandemic, substantial segments
of the medical industry have shifted to telemedicine in order to make patient
visits more suitable. Based on a video visit during the COVID-19 outbreak,
patients who were subsequently confirmed as having CIDP and managed with
intravenous immunoglobulins greatly improved clinical examination and
electrodiagnostic tests. Telemedicine cannot be used to conduct neuromuscular
assessment because of technical restrictions. Thus, COVID-19 greatly impacted
the global chronic inflammatory demyelinating polyneuropathy (CIDP) market.
Global Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) Market Dynamics
treatments
and therapies.
Drivers
- Increasing Drug Approvals
Growing drug approvals by several regulatory authorities is
projected to boost the global chronic inflammatory demyelinating polyneuropathy
(CIDP) treatment market growth. For instance, in March 2017, CSL Behring
received U.S. FDA approval for Privigen, an immunoglobulin therapy for treating
chronic inflammatory demyelinating polyneuropathy (CIDP) disorder.
Additionally, in March 2018, CSL Behring again received U.S. FDA approval for
Hizentra. It is a type of subcutaneous immunoglobulin therapy that prevents
relapsing neuromuscular disability. The approval was based on the results of
phase III clinical trial. These factors are expected to boost the global
chronic inflammatory demyelinating polyneuropathy (CIDP) treatment market
growth.
·
Growing Advanced
Technologies
The rising introduction of several advanced
technologies in diagnostic tools for chronic inflammatory demyelinating
polyneuropathy (CIDP) disorder is anticipated to boost the global chronic
inflammatory demyelinating polyneuropathy (CIDP) treatment market growth. For
instance, in July 2018, according to National Centre for Biotechnology
Information (NCBI) reports, a technique called multifocal visional evoked
potential is meant to diagnose CIDP and can detect abnormalities in the optic
nerve fiber, thus ensuring higher accuracy in diagnosis.
Opportunities
- Increasing Development of Drugs
There are numerous potential drugs in the pipeline
that are used for the treatment of chronic inflammatory demyelinating
polyneuropathy (CIDP). For instance, in January 2016, Shire plc, began clinical
trials of HyQvia for the treatment of chronic inflammatory demyelinating
polyneuropathy (CIDP) disorder. It is a type of intravenous immunoglobulin
therapy approved for primary immunodeficiency treatment and is presently in
phase III of clinical trials. All these factors are also contributing in the
growth of the market.
- Growing Autoimmune Disorders
As per the American Autoimmune Related Diseases
Association, autoimmune disorders affect around 50 million Americans in 2017.
Research and development in plasma-derived therapies will likely boost the
expansion in the market value of chronic inflammatory demyelinating
polyneuropathy. Therefore, this set of population requires high-end use of
therapeutics which in return creates more opportunities for the market growth.
Market
Segmentation:
Treatment
- Intravenous
Immunoglobulin
- Corticosteroids
- Aristocort
- Bubbli-Pred
- Celestone
- Plasmapheresis
- Physiotherapy
- Others
Diagnosis
- Electrodiagnostic
Testing
- Nerve Conduction
- EMG
- Spinal Fluid
Analysis
- Others
Route of Administration
- Oral
- Intravenous
- Others
End-Users
- Hospitals
- Homecare
- Specialty
Clinics
- Others
Distribution Channel
- Hospital
Pharmacy
- Retail Pharmacy
- Online Pharmacies
- F. Hoffmann-La
Roche Ltd. (Switzerland)
- Mylan N.V.
(U.S.)
- Teva
Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc.
(U.S.)
- GSK plc (U.K.)
- Novartis AG
(Switzerland)
- AstraZeneca
(U.K.)
- Johnson &
Johnson Private Limited (U.S.)
- Sun
Pharmaceutical Industries Ltd. (India)
- Merck & Co.,
Inc. (U.S.)
- Lilly (U.S.)
- Amgen Inc.
(U.S.)
- Actelion
Pharmaceuticals Ltd (Switzerland)
Regional
Analysis:
The chronic inflammatory demyelinating
polyneuropathy (CIDP) market is analyzed and market size insights and trends
are provided by treatment, diagnosis, route of administration, end-user,
distribution channel as referenced above.
The major countries covered in the global chronic
inflammatory demyelinating polyneuropathy (CIDP) market report are the U.S., Canada
and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland,
Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan,
India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia,
Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi
Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa
(MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of
South America as part of South America.
North America is considered to
have the highest lucrative growth in the forecast period due to the high-income
of the countries and favorable reimbursement.
Asia-Pacific is dominating the
market due to rise in the research and development associated with
plasma-derived medicines and rise in the government support via awareness
programs and drug approvals in this region.
The country section of the report also provides
individual market impacting factors and changes in regulation in the market
domestically that impacts the current and future trends of the market. Also,
the presence and availability of global brands and their challenges faced due
to large or scarce competition from local and domestic brands, impact of
domestic tariffs and trade routes are considered while providing forecast
analysis of the country data.
About US:
Analytics Market Research is an established
market analytics and research firm with a domain experience sprawling across
different industries. We have been working on multi-county market studies right
from our inception. Over the time, from our existence, we have gained laurels
for our deep -rooted market studies and insightful analysis of different
markets.
Our strategic market analysis and capability to
comprehend deep cultural, conceptual and social aspects of various tangled
markets has helped us make a mark for ourselves in the industry. Analytics Market
Research is a frontrunner in helping numerous companies; both regional and
international to successfully achieve their business goals based on our
in-depth market analysis. Moreover, we are also capable of devising market
strategies that ensure guaranteed customer bases for our clients.
Contact US:
Analytics Market Research
99 WALL STREET, #2124 NEW YORK, NY 10005
Phone: +1(650)-666-4592
Email: sales@analyticsmarketresearch.com
Web: https://analyticsmarketresearch.com/
Comments
Post a Comment